Together these data suggest MYCN and ALYREF bind together in a transcriptional coactivator complex to increase USP3 transcript levels, consequently reducing MYCN ubiquitination, and further increasing MYCN protein to the levels required to drive neuroblastoma tumorigenesis. The gene discussed is ALYREF; the disease is neuroblastoma.